According to our study results revealing protumor functions of ADAM9 in PCa, IMGC936 and other novel pharmacological agents that inhibit ADAM9 should be explored in preclinical investigations and clinical trials with PCa patients. Here, ADAM9 is linked to posterior cortical atrophy.